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OBJECTIVES: To analyze the cost-effectiveness of Omalizumab in addition to Stan-
dard of Care (SoC) in the treatment of paediatric patients (6 yeas-old) with severe
uncontrolled asthma from the perspective of the Public Health Care System in
México. METHODS: A Markov model, with cycle duration of 2 weeks, was designed
to analyze the cost-effectiveness of Omalizumab vs SoC. Effectiveness was evalu-
ated by the number of exacerbations avoided. The model identifies 4 health-states,
and death based on symptoms and exacerbations with and without omalizumab.
Transition probabilities were obtained from two clinical studies identified after a
systematic review, with approximately 627 patients. Omalizumab showed a reduc-
tion of 43% in the asthma exacerbation rate vs SoC (Lanier, 2009). Model time
horizon was 20 years, with treatment duration of 6 years. A discount rate of 5% was
used for costs and outcomes. Direct medical costs associated with exacerbations
were elicited from an expert panel of clinicians and valuated by the unitary cost list
of the Mexican Institute of Social Security. Drug costs are those from public tenders
2012. (US$1MX$13.8). Probabilistic sensitivity analysis was performed using
Monte Carlo technique. RESULTS: The expected 20–year costs and number of ex-
acerbations per patient with each treatment were: Omalizumab US$96,483/31.52;
and SoC US$49,857/39.84. It represents 8.3 exacerbations avoided with an incre-
mental cost-effectiveness ratio of US$5,617 per exacerbation avoided for omali-
zumab versus SoC, below the Mexican threshold of 1GDP per-cápitaUS$8,586.
Probabilistic sensitivity analysis showed omalizumab was below the threshold 95%
of the times, according to the acceptability curve. The model is more sensitive to
changes in efficacy than price. CONCLUSIONS: For paediatric patients with severe
uncontrolled asthma, treatment with omalizumab is a cost-effective option com-
pared with current SoC in the health system. The higher drug acquisition cost of
Omalizumab is off-set by the lower rate of exacerbations seen with patients on
omalizumab and their related costs.
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OBJECTIVES: To assess the cost-effectiveness of adding omalizumab to standard
therapy (ST) alone in patients with uncontrolled severe allergic asthma from Bra-
zilian public health care system perspective. METHODS: A Markov model compar-
ing lifetime ST with omalizumab add-on therapy was developed based on efficacy
data from INNOVATE (Phase III trial, N419, 28 weeks). Outcomes are expressed as
clinically significant exacerbation (CSE) and clinically significant severe exacerba-
tion (CSSE) avoided. A CSE is defined in INNOVATE as worsening of asthma requir-
ing treatment with rescue systemic corticosteroids and a CSSE is defined as PEF/
FEV1 60% of personal best, in addition to requiring rescue treatment with
corticosteroids or requiring emergency room treatment or hospitalization. Re-
sources use data (physician consultations, laboratory tests, emergency rooms vis-
its, hospitalizations, drug treatments) was obtained from INNOVATE and valued
from the perspective of health care payer. In the model, subjects move back and
forth between daily symptoms (optimized asthma control) and the CSE or CSSE
states, as they have exacerbations and then recover. Patients can have several CSE
sequentially, or can remain with no exacerbation for a long period, determined by
the transition probabilities. The death states are separated into deaths from all
causes and asthma-related deaths due to severe exacerbations. One-way-sensitiv-
ity-analysis (OWSA) was performed. Annual discount rate of 5% was applied both
to costs and outcomes. RESULTS: Base case analysis showed that more CSE and
CSSE were avoided with omalizumab add-on therapy than ST alone (incremental of
17.57 and 9.27 respectively) with additional cost of BRL 122,392. Hence, omalizumab
ICERs are BRL 6,967/CSE avoided and BRL 13,198/CSSE avoided (1BRL0.487USD).
OWSA confirms the favorable results of base case for omalizumab. CONCLUSIONS:
The pharmacoeconomic evaluation confirms that omalizumab add-on therapy is
very cost-effective versus ST in the treatment of patients with uncontrolled severe
allergic asthma (i.e. 1GDP per capita or BRL 19,000; WHO threshold).
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OBJECTIVES: To estimate cost-effectiveness of montelukast in 2 – 6-year-old chil-
dren with mild-moderate persistent asthma in Belarus. METHODS: A one-year
decision tree model of asthma for a hypothetical cohort of 100 patients taking
either montelukast (4 mg/day) or budesonide inhalation suspension (0,5mg/day) or
lack of basis therapy has been constructed on the basis of the results of randomized
clinical studies and local data. The number and duration of asthma exacerbations,
the number of days with use of short-acting 2-receptor agonist (salbutamol) in-
haler, the number of salbutamol puffs per day have been calculated. Direct and
indirect costs have been calculated (U.S. $, 2012). The cost-effectiveness ratio (CER)
for montelukast, budesonide inhalation suspension or lack of basis therapy per
number of days without asthma attacks, exacerbations, use of short-acting 2-
receptor agonists has been quantified. Sensitivity analysis has been performed.
The duration and severity of asthma exacerbations, various types of pharmaco-
therapy were taken into consideration when sensitivity analysis was being made.
RESULTS: In 2 – 6-year-old children with mild-moderate persistent asthma the CER
of oral montedukast use was $4.1 per day without asthma attacks, exacerba-
tions, use of short-acting 2-receptor agonists, CER of budesonide inhalation
suspension use by nebulizer was $5.6, CER of lack of basis therapy was $6.9. The
resulting trend persisted during the sensitivity analysis. CONCLUSIONS: In Repub-
lic of Belarus the use of oral montelukast is considered to be cost-effective in
comparison to budesonide inhalation suspension or a lack of basis therapy in 2 –
6-year-old children with mild-moderate persistent asthma.
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OBJECTIVES:Global strategy for the prevention and treatment of bronchial asthma
(GINA) recommends antileukotriene drugs as second-line therapy, also while treat-
ing children. The cost-effectiveness analysis (CEA) of montelukast in 6-14-year-old
children suffering from mild-moderate persistent asthma has been performed to
determine economic advisability of its applying in Republic of Belarus. METHODS:
On the basis of the results of randomized studies and local data, the model of
asthma process for a hypothetical cohort of 100 patients taking either montelukast
(5 mg/day) or fluticasone - aerosol (250 mcg/day) has been constructed. The number
and duration of asthma exacerbations, the number of days with the use of short-
acting 2-receptor agonist (salbutamol) inhaler, the number of salbutamol puffs per
twenty-four hours have been chosen as important criteria influencing the process
of the disease and economic burden. RESULTS: In children older than 6 with mild-
moderate persistent asthma the priority medicine is an inhaled corticosteroid (ICS)
(CERfluticasone – 1, 45$ per day without attacks, aggravations, use of salbutamol as
compared to CERmontelukast – 2, 62$). The trends obtained in the main analysis
remain unchanged (CEAfluticasone – 1, 67$ for one day without attacks, aggravations,
use of salbutamol as compared to CEAmontelukast – 2, 98$) even if changes in the
period of hospitalization of the patients occur (an increase up to 14.7 days) as well
as in case of extension of exacerbation treatment or severity of exacerbation and
additional medical aid in the emergency room for one or two days. If indirect costs
caused by one of the parents’ absence at work are excluded from the analysis, the
priority medicine is an ICS: (CEAfluticasone – 1, 19$ as compared to CEAmontelukast – 1,
95$). CONCLUSIONS: In the Republic of Belarus inhaled corticosteroid is the prior-
ity medicine in children older than 6 years who are able to master the technique of
inhalation.
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OBJECTIVES: We hypothesized that one central laboratory would be more cost-
effective than several local laboratories because price of single Chlamylege test
depends on number of simultaneous tests performed. Incidence of pneumonia
requiring hospitalization in Poland is app.4/1000 persons/year. For hypothetical
population of one million people 4 000/ year will require hospitalization for pneu-
monia (VIP). We established seasonal incidence using clinical database of Military
Medical Institute Warsaw. New statistical method (Queuing Model)was used.
METHODS: Two simulation models were constructed for one million inhabitants:
one, where four hospital laboratories exist, performing 10-50 tests. Second, where
large central laboratory exists performing 50-200 tests. Three scenarios of morbid-
ity were established: 1) 3000 outpatients, 1000 inpatients, equal number of patients
over year; 2) 3000 outpatients, 1000 inpatients, number of patients/month related
to seasonality (4 seasons specified); 3) increased influx of patients: 12000 outpa-
tients and 4000 inpatients; number of patients/month related to seasonality.
RESULTS: 1) in central laboratory significantly smaller number of samples were
tested (mean 0.25vs0.75); 2) quarter 1 (increased patients influx) % tested in central
laboratory was significantly higher but still smaller than in the local labs
(0.92vs.0.95) whereas in quarter 3 (decreased patients influx) less tests per-
formed(0.2777 vs. 0.0005); and 3) % of tests made in central lab is much higher, but
still not exceeding number of tests performed in local labs ( 0.82vs.0.83). Central
laboratory performed less tests comparing to local labs and periods of inactivity
were noted which significantly increased cost of a single test. CONCLUSIONS: Ac-
cording to Queuing Model it was confirmed that creation of the central laboratory is
not reasonable in terms of costs. We conclude that Queuing Statistical Model can
be a useful tool for preliminary assessment ofthe cost-effectiveness of hypothe-
sized research methodology.
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OBJECTIVES: Clinical evidence shows that fewer infants fed for up to 4 months
with 100% partially hydrolyzed whey formula (pHF-W) subsequently develop
atopic dermatitis (AD) over up to 6 years than infants fed standard formula (SF) or
extensively hydrolyzed whey formula (eHF-W). The present study assessed the
cost-effectiveness of pHF-W compared to SF and eHF-W for the prevention of AD in
Germany. METHODS: A Markov cohort model was used to assess over a period of 6
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